Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 184 (6) , 2313-2319
- https://doi.org/10.1016/j.juro.2010.08.012
Abstract
Purpose: We assessed the cardiovascular safety profile of degarelix, a new gonadotropin-releasing hormone antagonist.Materials and Methods: This is the first report to our knowledge on cardiovascul...Keywords
This publication has 16 references indexed in Scilit:
- DegarelixDrugs, 2009
- Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2009
- A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North AmericaJournal of Urology, 2008
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Metabolic and cardiovascular effects of androgen deprivation therapyBJU International, 2008
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate CancerEuropean Urology, 2008
- Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Current Urology Reports, 2008
- Testosterone in Obesity, Metabolic Syndrome and Type 2 DiabetesPublished by S. Karger AG ,2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei HerzkrankenActa Medica Scandinavica, 1920